Shares fly as AstraZeneca finally returns to growth

14 February 2019

Last year AstraZeneca’s (LSE: AZN) annual results statement showed that French chief executive Pascal Soriot had missed a promise to reverse his firm’s longstanding decline in revenues.

This year’s statement shows Mr Soriot has finally succeeded in returning the firm to growth, sending shares in the British drugmaker up over 8% by late afternoon in London on Thursday.

AstraZeneca has beaten expectations in its most recent final quarter and full-year 2018 financial results statement. Driven by its oncology division, the final quarter saw strong performance, with product sales growth of 5%, to $5.7 billion. For the full year, sales increased 4% to $21 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK